共 50 条
- [1] Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc AnalysesJOURNAL OF UROLOGY, 2021, 205 (05): : 1361 - 1370Armstrong, Andrew J.Shore, Neal D.Szmulewitz, Russell Z.Petrylak, Daniel P.Holzbeierlein, JeffreyVillers, ArnauldAzad, ArunAlcaraz, AntonioAlekseev, BorisIguchi, TaroGomez-Veiga, FranciscoRosbrook, BradLee, Ho-JinHaas, Gabriel P.Stenzl, Arnulf
- [2] Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Shore, Neal D.Armstrong, Andrew J.Szmulewitz, Russell ZeligPetrylak, Daniel PeterHolzbeierlein, JeffreyVillers, ArnauldAzad, ArunAlcaraz, AntonioAlekseev, BorisIguchi, TaroGomez-Veiga, FranciscoRosbrook, BradLee, Ho-JinHaas, Gabriel P.Stenzl, Arnulf
- [3] Androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: ARCHESSWISS MEDICAL WEEKLY, 2019, 149 : 16S - 16Svon Bueren, MoritzArmstrong, Andrew J.Szmulewitz, RussellPetrylak, DanielVillers, ArnauldAzad, ArunAlcaraz, AntonioAlekseev, BorisIguchi, TaroShore, Neal D.Rosbrook, BradSugg, JenniferBaron, BenoitChen, LucyStenzl, Arnulf
- [4] The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHESEUROPEAN UROLOGY, 2023, 84 (02) : 229 - 241Armstrong, Andrew J.Iguchi, TaroAzad, Arun A.Villers, ArnauldAlekseev, BorisPetrylak, Daniel P.Szmulewitz, Russell Z.Alcaraz, AntonioShore, Neal D.Holzbeierlein, JeffreyGomez-Veiga, FranciscoRosbrook, BradZohren, FabianHaas, Gabriel P.Gourgiotti, GeorgiaEl-Chaar, NaderStenzl, Arnulf
- [5] Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trialANNALS OF ONCOLOGY, 2016, 27Stenzl, A.Krivoshik, A.Baron, B.Hirmand, M.Armstrong, A.
- [6] ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Armstrong, Andrew J.Szmulewitz, Russell ZeligPetrylak, Daniel PeterHolzbeierlein, Jeffrey M.Villers, ArnauldAzad, ArunAlcaraz, AntonioAlekseev, Boris YakovlevichIguchi, TaroShore, Neal D.Rosbrook, BradBaron, BenoitChen, Lucy F.Stenzl, Arnulf
- [7] The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Armstrong, Andrew J.Iguchi, TaroAzad, ArunVillers, ArnauldAlekseev, BorisPetrylak, Daniel P.Szmulewitz, Russell ZeligAlcaraz, AntonioShore, Neal D.Holzbeierlein, JeffreyGomez-Veiga, FranciscoRosbrook, BradZohren, FabianHaas, Gabriel P.Gourgioti, GeorgiaEl-Chaar, Nader N.Stenzl, Arnulf
- [9] ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate CancerJOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) : 2974 - +Armstrong, Andrew J.Szmulewitz, Russell Z.Petrylak, Daniel P.Holzbeierlein, JeffreyVillers, ArnauldAzad, ArunAlcaraz, AntonioAlekseev, BorisIguchi, TaroShore, Neal D.Rosbrook, BradSugg, JenniferBaron, BenoitChen, LucyStenzl, Arnulf
- [10] ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levelsANNALS OF ONCOLOGY, 2020, 31 : S523 - S524Alcaraz, A.Szmulewitz, R. Z.Shore, N.Crawford, E. D.Petrylak, D. P.Holzbeierlein, J.Villers, A.Azad, A. A.Alekseev, B.Iguchi, T.Gomez-Veiga, F.Rosbrook, B.Sugg, J.Haas, G. P.Stenzl, A.Armstrong, A. J.